USA - NASDAQ:SYNH - US87166B1026 - Common Stock
The current stock price of SYNH is 42.98 USD. In the past month the price increased by 0.7%. In the past year, price decreased by -8.84%.
 Symbol   |  Company Name   |  TA   |  FA   |  PE   |  Market Cap   | 
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 25.22 | 213.30B | ||
| DHR | DANAHER CORP | 27.76 | 153.28B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 143.78 | 46.90B | ||
| A | AGILENT TECHNOLOGIES INC | 26.55 | 41.02B | ||
| IQV | IQVIA HOLDINGS INC | 18.39 | 36.36B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 34.4 | 28.98B | ||
| WAT | WATERS CORP | 28.26 | 20.57B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 39.57 | 20.12B | ||
| ILMN | ILLUMINA INC | 27.52 | 18.44B | ||
| MEDP | MEDPACE HOLDINGS INC | 41.54 | 16.69B | ||
| TEM | TEMPUS AI INC | N/A | 15.41B | ||
| ICLR | ICON PLC | 12.8 | 13.13B | 
 Syneos Health, Inc. engages in the provision of biopharmaceutical solutions. The company is headquartered in Morrisville, North Carolina and currently employs 28,768 full-time employees. The company went IPO on 2014-11-07. The firm operates through two business segments: Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers global services for the development of diagnostics, drugs, biologics, devices, and digital therapeutics that span Phase I to IV of clinical development. The Clinical Solutions segment offers individual services including product development, project management, protocol development, investigational site recruitment, and clinical monitoring. The Commercial Solutions segment provides commercialization services, including deployment solutions, communications solutions (public relations, advertising, and medical communications), and consulting services. The Company’s customers include small, mid-sized, and large companies in the biopharmaceutical, biotechnology, and medical device industries.
SYNEOS HEALTH INC
1030 Sync Street
Morrisville NORTH CAROLINA 27560 US
CEO: Alistair Macdonald
Employees: 28768
Phone: 19198769300.0
Syneos Health, Inc. engages in the provision of biopharmaceutical solutions. The company is headquartered in Morrisville, North Carolina and currently employs 28,768 full-time employees. The company went IPO on 2014-11-07. The firm operates through two business segments: Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers global services for the development of diagnostics, drugs, biologics, devices, and digital therapeutics that span Phase I to IV of clinical development. The Clinical Solutions segment offers individual services including product development, project management, protocol development, investigational site recruitment, and clinical monitoring. The Commercial Solutions segment provides commercialization services, including deployment solutions, communications solutions (public relations, advertising, and medical communications), and consulting services. The Company’s customers include small, mid-sized, and large companies in the biopharmaceutical, biotechnology, and medical device industries.
The current stock price of SYNH is 42.98 USD. The price increased by 0.02% in the last trading session.
SYNH does not pay a dividend.
SYNH has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
SYNH stock is listed on the Nasdaq exchange.
SYNEOS HEALTH INC (SYNH) has a market capitalization of 4.46B USD. This makes SYNH a Mid Cap stock.
SYNEOS HEALTH INC (SYNH) will report earnings on 2023-11-02, before the market open.
ChartMill assigns a technical rating of 7 / 10 to SYNH. When comparing the yearly performance of all stocks, SYNH turns out to be only a medium performer in the overall market: it outperformed 45.73% of all stocks.
ChartMill assigns a fundamental rating of 5 / 10 to SYNH. SYNH has an average financial health and profitability rating.
Over the last trailing twelve months SYNH reported a non-GAAP Earnings per Share(EPS) of 3.78. The EPS decreased by -23.79% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 1.31% | ||
| ROA | 0.88% | ||
| ROE | 2.04% | ||
| Debt/Equity | 0.77 | 
16 analysts have analysed SYNH and the average price target is 43.35 USD. This implies a price increase of 0.86% is expected in the next year compared to the current price of 42.98.
For the next year, analysts expect an EPS growth of -25.43% and a revenue growth -2.82% for SYNH